Observational data show that certain types of sulfonylureas for the treatment of type 2 diabetes are associated with more cardiovascular events compared to other types, such as glimepiride.
The new 2023 American Diabetes Association Standards of Care address management of diabetes and its complications, as well as social determinants of health.